{"url_path":"/sec/cbio/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q/A","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-044713-index.html","accession_number":"0001628280-26-044713","cik":"0001253689","ticker":"CBIO","issuer_name":"CRESCENT BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-044713-index.html","primary_entity_key":"0001253689","primary_entity_name":"CRESCENT BIOPHARMA, INC."},"word_count":743,"has_tables":true,"body_markdown":"cbio-20260331\n0001253689--12-31Q1true2026xbrli:shares00012536892026-01-012026-03-3100012536892026-04-240001253689cbio:JoshuaBrummMember2026-01-012026-03-310001253689cbio:JonathanMcNeillMember2026-01-012026-03-310001253689cbio:EllieImMember2026-01-012026-03-310001253689cbio:JanPinkasMember2026-01-012026-03-310001253689cbio:RichardScalzoMember2026-01-012026-03-310001253689cbio:RyanLynchMember2026-01-012026-03-310001253689cbio:BarbaraBisphamHaleMember2026-01-012026-03-31\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n________________________________\n\nFORM 10-Q/A\n\nAmendment No. 1\n\n________________________________\n\n(Mark One)\n\nxQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\noTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from _________ to _________\n\nCommission file number 001-36177\n\n________________________________\n\nCrescent Biopharma, Inc.\n\n(Exact name of registrant as specified in its charter)\n\n________________________________\n\nCayman Islands06-1686563\n\n(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)\n\n300 Fifth Avenue\n\nWaltham, MA\n02451\n\n(Address of Principal Executive Offices)(Zip Code)\n\nRegistrant’s telephone number, including area code: (617) 430-5595\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nOrdinary Shares, $0.001 par value per shareCBIO\nThe Nasdaq Capital Market\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.\n\nYes x No o\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).\n\nYes x No o\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and \"emerging growth company\" in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated fileroAccelerated filero\n\nNon-accelerated filer☒Smaller reporting company☒\n\nEmerging growth companyo\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.\n\no\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\n\nYes o No ☒\n\nAs of April 24, 2026, there were 27,571,935 of the issuer’s ordinary shares outstanding.\n\nExplanatory Note\n\nCrescent Biopharma, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, which was originally filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2026 (the “Original Filing”). This Amendment is being filed to revise Part II “Item 5. Other Information” by adding disclosure regarding Rule 10b5-1 trading arrangements (as defined in Item 408(a) of Regulation S-K), which was inadvertently omitted from the Original Filing.\n\nIn addition, as required by Rule 12b-15 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment, under Part II, Item 6 hereof, pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not including new certifications under Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) (Section 906 of the Sarbanes-Oxley Act of 2002), as no financial statements are being filed with this Amendment.\n\nOther than as expressly set forth herein, this Amendment does not, and does not purport to, amend, update or restate the information in the Original Filing or reflect any events that have occurred after the date the Original Filing was made. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original Filing was made. No changes have been made to the financial statements of the Company as contained in the Original Filing. Accordingly, this Amendment should be read together with the Original Filing and the Company’s other filings with the SEC.\n\nPart II - Other Information"}